Martin Huber
About Martin Huber
Professional Title and Leadership Roles
Martin Huber serves as the President and Chief Executive Officer, and he has showcased leadership capabilities in both small and large biopharmaceutical organizations. His roles have spanned various high-impact positions, including President, Head of R&D, and Chief Medical Officer at Xilio Therapeutics, Inc., and Chief Medical Officer at TESARO, Inc. Notably, he has been a member of Mersana’s Board of Directors since 2020.
Drug Development and Clinical Research Experience
Martin Huber has extensive experience in drug development, contributing to the approval of several oncology medicines, such as docetaxel, dostarlimab, niraparib, pembrolizumab, and trastuzumab. His career includes significant roles in oncology clinical development, drug safety, and pharmacovigilance with companies like Schering-Plough, Hoffmann-La Roche, and Rhone-Poulenc Rorer. He also held the position of Vice President, Oncology Clinical Research at Merck Research Laboratories.
Education and Early Career
Martin Huber received his medical degree from Baylor College of Medicine. He began his career as an Assistant Professor of Oncology at the University of Texas M.D. Anderson Cancer Center, marking the start of his journey in the oncology field.
Roles in Biopharmaceutical Companies
Throughout his career, Martin Huber has worked in various capacities at leading biopharmaceutical organizations. His tenure includes serving as Chief Medical Officer at TESARO, Inc., and subsequently as Senior Vice President, Clinical at GlaxoSmithKline plc post the acquisition of TESARO. He has demonstrated his expertise in different operational functions within the biopharma sector, highlighting his multifaceted experience in the industry.